Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)

Neoplasms Clinical Trial

Official title:

A Phase 1 Trial of MK-4280 as Monotherapy and in Combination With Pembrolizumab With or Without Chemotherapy or Lenvatinib (E7080/MK-7902) in Subjects With Advanced Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02720068
• Other study ID #: 4280-001
• Secondary ID: MK-4280-00118397
• Status: Completed
• Phase: Phase 1
• Start date: May 2, 2016
• Est. completion date: March 15, 2024

Study information

• Verified date: March 2024
• Source: Merck Sharp & Dohme LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a safety and pharmacokinetics study of favezelimab as monotherapy and in combination with pembrolizumab AND favezelimab/pembrolizumab as monotherapy in adults with metastatic solid tumors for which there is no available therapy which may convey clinical benefit. Part A of this study is a dose escalation design in which participants receive favezelimab as monotherapy or favezelimab in combination with pembrolizumab. Part B is a dose confirmation design to estimate the recommended Phase 2 dose (RP2D), as determined by dose-limiting toxicity, for favezelimab in combination with pembrolizumab or pembrolizumab and lenvatinib in participants with advanced solid tumors. Part B will also assess the efficacy of favezelimab as monotherapy; favezelimab in combination with pembrolizumab with and without chemotherapy; favezelimab in combination with pembrolizumab and lenvatinib; and favezelimab/pembrolizumab as monotherapy in expansion cohorts. Participants who have completed the initial course of treatment and have investigator-determined progressive disease may be eligible for a second course of an additional 17 cycles of study treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 482
• Est. completion date: March 15, 2024
• Est. primary completion date: March 15, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Part A and Part B: Has histologically or cytologically-confirmed metastatic solid tumor.

• Has measurable disease by immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) 1.1 criteria.

• Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.

• Demonstrates adequate organ function.

• If female, is not pregnant or breastfeeding, and if of child-bearing potential, is willing to use an adequate method of contraception for the course of the study and for at least 180 days after the last dose of chemotherapy, 120 days after the last dose of pembrolizumab or favezelimab, or 30 days after the last dose of lenvatinib, whichever occurs last.

• If male with a female partner(s) of child-bearing potential, both must agree to use an adequate method of contraception starting with the first dose of study drug through 95 days after the last dose of study drug.

Exclusion Criteria:

• Has had chemotherapy, radiation or biological cancer therapy within 4 weeks prior to the first dose of study drug,or has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) Grade 0 or 1 from the AEs due to cancer therapeutics administered more than 4 weeks earlier (this includes participants with previous immunomodulatory therapy with residual immune-related [ir]AEs).

• Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study drug.

• Has received previous treatment with another agent targeting the lymphocyte-activation gene 3 (LAG-3) receptor.

• Has received previous treatment with an immunomodulatory therapy (e.g., anti-programmed cell death-1/anti-programmed cell death-ligand 1 [anti-PD-1/anti-PD-L1] or cytotoxic T-lymphocyte-associated protein 4 [CTLA 4] agent) and was discontinued from that therapy due to a Grade 3 or higher irAE.

• Is expected to require any other form of antineoplastic therapy while on study.

• Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy in excess of replacement doses, or on any other form of immunosuppressive medication.

• Has a history of a previous, additional malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 5 years. Time frame exceptions include successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer or in situ cervical cancer, or other in situ cancers.

• Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

• Has had a severe hypersensitivity reaction to treatment with another monoclonal antibody.

• Has an active autoimmune disease or a documented history of autoimmune disease, except vitiligo or resolved childhood asthma/atopy.

• Has an active infection requiring therapy.

• Has history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.

• Has had a prior stem cell or bone marrow transplant.

• Has a known history of or screens positive for Human Immunodeficiency Virus (HIV), active chronic or acute Hepatitis B or Hepatitis C.

• Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.

• Is a regular user as determined by investigator judgement (including "recreational use") of any illicit drugs or has a recent history (within the last year) of substance abuse (including alcohol), at the time of signing informed consent.

• Has symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.

• Has clinically significant heart disease that affects normal activities.

• Has received a live-virus vaccine within 30 days of planned start of study drug. Seasonal flu vaccines that do not contain live virus are permitted.

Related Conditions & MeSH terms

• Neoplasms

Intervention

Biological:
• Favezelimab
IV infusion
• Pembrolizumab
IV infusion

Drug:
• Oxaliplatin
IV infusion
• Irinotecan
IV infusion
• Leucovorin (Calcium Folinate)
IV infusion
• Fluorouracil [5-FU]
IV infusion

Biological:
• Favezelimab/Pembrolizumab
IV infusion

Drug:
• Lenvatinib
Oral

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme LLC

References & Publications (2)

Garralda E, Sukari A, Lakhani NJ, Patnaik A, Lou Y, Im SA, Golan T, Geva R, Wermke M, de Miguel M, Palcza J, Jha S, Chaney M, Abraham AK, Healy J, Falchook GS. A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously — View Citation

Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) - Full Text View - ClinicalTrials.gov

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)		Up to approximately 52 weeks
Primary	Number of Participants Who Experience at Least One Adverse Event (AE)		Up to approximately 7 years
Primary	Number of Participants Who Discontinue Study Drug Due to an AE		Up to approximately 7 years
Secondary	Serum Concentration of Favezelimab When Administered as Monotherapy		At designated time points (Up to approximately 2 years)
Secondary	Serum Concentration of Favezelimab When Administered in Combination With Pembrolizumab		At designated time points (Up to approximately 2 years)
Secondary	Serum Concentration of Favezelimab When Administered in Combination With Pembrolizumab and mFOLFOX7		At designated time points (Up to approximately 2 years)
Secondary	Serum Concentration of Favezelimab When Administered in Combination With Pembrolizumab and FOLFIRI		At designated time points (Up to approximately 2 years)
Secondary	Serum Concentration of Favezelimab When Administered in Combination With Pembrolizumab and Lenvatinib		At designated time points (Up to approximately 2 years)
Secondary	Serum Concentration of Pembrolizumab When Administered in Combination With Favezelimab and mFOLFOX7		At designated time points (Up to approximately 2 years)
Secondary	Serum Concentration of Pembrolizumab When Administered in Combination With Favezelimab and FOLFIRI		At designated time points (Up to approximately 2 years)
Secondary	Serum Concentration of Pembrolizumab When Administered in Combination With Favezelimab and Lenvatinib		At designated time points (Up to approximately 2 years)
Secondary	Serum Concentration of Lenvatinib When Administered in Combination With Pembrolizumab and Favezelimab		At designated time points (Up to approximately 2 years)
Secondary	Objective Response Rate (ORR) as Determined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as Assessed by Investigator Review of Favezelimab Alone and in Combination With Pembrolizumab		Up to approximately 2 years
Secondary	ORR as Determined by RECIST 1.1 as Assessed by Investigator Review of Two Doses of Favezelimab in Combination With Pembrolizumab for Participants With Advanced Solid Tumors in Cohort E		Up to approximately 2 years
Secondary	ORR as Determined by RECIST 1.1 as Assessed by Investigator Review of Favezelimab in Combination With Pembrolizumab and mFOLFOX7 for Participants With Advanced Solid Tumors in Cohort B		Up to approximately 2 years
Secondary	ORR as Determined by RECIST 1.1 as Assessed by Investigator Review of Favezelimab in Combination With Pembrolizumab and FOLFIRI for Participants With Advanced Solid Tumors in Cohort B		Up to approximately 2 years
Secondary	ORR as Determined by RECIST 1.1 as Assessed by Investigator Review of Favezelimab in Combination With Pembrolizumab and Lenvatinib for Participants With Advanced Solid Tumors in Cohort G		Up to approximately 2 years
Secondary	Serum Concentration of Favezelimab When Administered as a Co-Formulation With Pembrolizumab (MK-4280A)		At designated time points (Up to approximately 2 years)
Secondary	Serum Concentration of Favezelimab When Administered Sequentially With Pembrolizumab		At designated time points (Up to approximately 2 years)
Secondary	Serum Concentration of Pembrolizumab When Administered as a Co-Formulation With Favezelimab (MK-4280A)		At designated time points (Up to approximately 2 years)
Secondary	Serum Concentration of Pembrolizumab When Administered Sequentially With Favezelimab		At designated time points (Up to approximately 2 years)

External Links

•   Merck Clinical Trials Information